Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.
Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 antibody from Japanese pharmaceutical manufacturer Takeda.
Taiwan-based Personal Genomics Taiwan has taken gene-sequencing rival Pacific Biosciences to court in the US, over alleged patent infringement.
Taiwanese company JHL Biotech will stop developing biosimilar versions of Genentech’s drugs as part of a memorandum of understanding signed by the parties to end trade secrets litigation.
Indian drugmaker Lupin and German pharma company Boehringer Ingelheim have formed an alliance to develop a therapy for patients with difficult-to-treat cancers.
Hong Kong customs authorities have carried out a series of raids resulting in the seizure of counterfeit vaccines worth over HKD $1 million, some containing poison.
PepsiCo India is withdrawing its lawsuits against nine farmers in the Gujarat region who it accused of growing a protected variety of potato used to make the company’s ‘Lay’s’ brand of crisps.
PepsiCo India is attempting to settle a lawsuit against four Indian farmers who the food and drink company say infringed its IP by growing a protected variety of potato.
Duane Morris & Selvam has strengthened its IP practice with the addition of John Alison from Winston & Strawn.
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.